Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01102257
Other study ID # 05-1099
Secondary ID 1R34EY017626
Status Completed
Phase Phase 2/Phase 3
First received April 9, 2010
Last updated July 20, 2012
Start date January 2010
Est. completion date March 2011

Study information

Verified date July 2012
Source Asbell, Penny, M.D.
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The purpose of this study is to test a protocol investigating the efficacy of omega-3 fatty acids in treating dry eye disease. The study is termed "feasibility" because its purpose is to demonstrate an ability to execute the proposed protocol with compliance at two sites rather than generate statistically relevant data concerning the safety and efficacy of the supplement in patients with dry eye disease.


Description:

Dry eye disease (DED) is a common but often inadequately treated disease of the tears and surface of the eye. It can cause poor vision and chronic pain and is more frequent with increasing age. Inflammation may be an important component of this disease. This is supported by the observation that cyclosporine, a drug that targets the immune system, is approved for and effectively treats DED. Inflammatory processes likely produce ocular surface damage and contribute to chronic DED. Because not all people with DED respond to current anti-inflammatory treatments, other immune-modulating treatments would be of value. Furthermore, despite a great deal of evidence supporting DED as an inflammatory disease, not all researchers currently agree with this classification. More data that specifically measures inflammatory responses in DED needs to be collected in a well-characterized patient population and correlated with signs and symptoms of DED in order to improve our understanding and classification of the disease.

Essential Fatty Acids (EFA) have been shown to diminish inflammatory responses in many human inflammatory diseases, and interest in the use of omega-3 and omega-6 fatty acids for disease treatment has resulted in several small studies as well as the use (and over-the-counter availability) of EFA-containing nutritional supplements, including several specifically for the treatment of DED. Despite this interest in EFA for DED, there are no strong empirical data from a well-controlled randomized controlled trial RCT supporting the use of EFA for DED. We postulate that DED is an inflammatory disease and hypothesize that EFA can mediate immune responses, thus improving DED signs, symptoms and associated measures of inflammation. The proposed three month feasibility study allows us the chance to demonstrate our ability to successfully execute our own protocol with compliance from the study patients before we begin the process of initiating a full-scale multi-center trial.


Recruitment information / eligibility

Status Completed
Enrollment 23
Est. completion date March 2011
Est. primary completion date July 2010
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 90 Years
Eligibility Inclusion Criteria:

1. Sign and date the informed consent form approved by the IRB.

2. = 18 years of age

3. Demonstrate at least 2 of the 4 following signs in the same eye at two consecutive visits (Visit 1: 7 - 21 days prior to randomization, and Visit 2: day of randomization).

1. Conjunctival staining present = 1

2. Corneal fluorescein staining present = 1

3. Tear film break up time (TFBUT) = 7 seconds

4. Schirmer test = 7 mm/5min

4. Demonstrate symptoms of dry eye disease (OSDI score of at least 22 at screening visit and at least 15 at randomization visit).

5. Use or desire to use artificial tears on average of 2 times per day in the 2 weeks preceding study entry (run in period). No newly diagnosed patients can be enrolled and if a new patient wants to participate, she/he must be put on tears and re-evaluated in 6 months.

6. Intraocular pressure (IOP) = 5 mmHg and = 22 mmHg in each eye.

7. Women of child-bearing potential must agree to use a reliable method of contraception during study participation, and must demonstrate a negative urine pregnancy test at screening visit.

8. Be willing/able to return for all study visits and to follow instructions from the study investigator and his/her staff.

9. Be able to swallow large, soft gelcaps

Exclusion Criteria:

1. Patients who are allergic to ingredients of the active or placebo pills (fish, olive oil).

2. Current diagnosis of ocular infection (e.g. bacterial, viral or fungal).

3. History of ocular herpetic keratitis.

4. Eye surgery (including cataract surgery) within 6 months prior to randomization.

5. Previous LASIK surgery

6. Pregnant or nursing/lactating

7. Participation in a study of an investigational drug or device within the past 30 days.

8. Recent (= 3 months) initiation of use of systemic corticosteroids or other immunosuppressive agent and/or is planning to change treatment during study participation

9. Cognitive or psychiatric deficit that precludes informed consent or ability to perform requirements of the investigation.

10. Contact lens wearers

11. Use of glaucoma medication or history of surgery for glaucoma.

12. Recent (= 3 months) insertion of punctual plugs.

13. Using punctual plugs but unwilling to commit to their use for the duration of the study.

14. Unwilling to commit to same brand of artificial tears throughout the study.

15. Current use of EPA/DHA supplements in excess of 1 gram/day.

16. Recent (= 6 months) initiation of use of Restasis.

17. Use of Restasis but unwilling to commit to use of Restasis for the duration of the study.

18. Discontinued use of Restasis within the last 3 months.

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment


Intervention

Drug:
Omega-3 EFA Supplement
The total daily dose from the 5 capsules in treatment group will be 3.0 grams of omega-3 EFAs comprised of: 2000 mg EPA 1000 mg DHA
Olive Oil
Placebo group will take 5 capsules a day containing 3.0 grams of olive oil

Locations

Country Name City State
United States Mount Sinai School of Medicine New York New York

Sponsors (2)

Lead Sponsor Collaborator
Asbell, Penny, M.D. National Eye Institute (NEI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change on Ocular Surface Disease Index (OSDI) 90 +/- 14 days following initiation of drug regimen Yes
Primary Change in REd Blood Cell(RBC) Membrane Fatty Acid(FA) Content Baseline and 3 Months No
Secondary Change on Brief Ocular Discomfort Inventory (BODI) 90 +/- 14 days following initiation of drug regimen Yes
Secondary Change on Impact of Dry Eye on Everyday Life (IDEEL) 90 +/- 14 days following initiation of drug regimen Yes
Secondary Change in Quality of Life Associated With Chronic Pain 90 +/- 14 days following initiation of drug regimen Yes
Secondary Change in the Ocular Surface 90 +/- 14 days following initiation of drug regimen Yes
Secondary Change in Schirmer's 90 +/- 14 days following initiation of drug regimen Yes
Secondary Change in Relevant Biomarkers: HLA-DR, MUC 5A, Cytokines 90 +/- 14 days following initiation of drug regimen Yes
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04425551 - Effect of Micropulse Laser on Dry Eye Disease Due to Meibomian Gland Dysfunction N/A
Not yet recruiting NCT06379685 - Study to Evaluate the Safety and Tolerability of PRO-190 Ophthalmic Solution Compared to Systane Ultra® on the Ocular Surface. Phase 1
Recruiting NCT04701086 - 3 Month Study of Cationorm Pro Versus Vismed in Adults With Dry Eye Disease Related to Keratitis or Keratoconjunctivitis N/A
Active, not recruiting NCT03697876 - Safety and Tolerability of the Ophthalmic Gel PRO-165 Versus Artelac® Nightime Gel Phase 1
Completed NCT02910713 - Evaluation of Dry Eye Symptoms in CAE With Application of Intranasal Neurostimulation N/A
Terminated NCT02815293 - Topical Ophthalmic AGN-195263 for the Treatment of Evaporative Dry Eye Phase 3
Completed NCT04104997 - A Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of GLH8NDE After Single and Mutiple Ocular Administrations in Healthy Korean and Caucasian Volunteers Phase 1
Recruiting NCT02595606 - 0.3% Sodium Hyaluronate in the Treatment of Dry Eye of Diabetic Patients Phase 4
Completed NCT01711424 - An Observational Study of OPTIVE PLUS® for the Treatment of Dry Eye Disease N/A
Completed NCT01015209 - Safety and Tolerability of Chitosan-N-acetylcysteine Eye Drops in Healthy Young Volunteers Phase 1
Completed NCT01202747 - Evaluation of Screening Methods for Treatment of Meibomian Gland Dysfunction Phase 2/Phase 3
Completed NCT00969280 - Acupuncture for Dry Eye Syndrome Phase 3
Completed NCT01496482 - Comparison of Evaporimetry With the Established Methods of Tear Film Measurement N/A
Completed NCT00756678 - Efficacy and Acceptability of Two Lubricant Eye Drops Phase 4
Completed NCT00739713 - Effects of Sea Buckthorn Oil on Dry Eye N/A
Completed NCT00349440 - Efficacy of Cyclosporine for the Prevention and Treatment of Dry Eye Symptoms Following LASIK or Photorefractive Keratectomy Phase 4
Completed NCT00370747 - Efficacy and Safety Study for Ecabet Ophthalmic Solution for Treating Dry Eye Syndrome Phase 2
Completed NCT05162261 - to Evaluate the Effectiveness and Safety of the Tixel® , VS LipiFlow® in the Treatment of Meibomian Gland Dysfunction N/A
Completed NCT02871440 - A Two Comparator, Controlled Phase 3 Study in Patients With and Without Evaporative Dry Eye Phase 3
Completed NCT05042960 - Computer Screen Properties Study N/A